Skip to main content
. 2020 Jun 10;18:1403–1413. doi: 10.1016/j.csbj.2020.05.026

Fig. 3.

Fig. 3

Comparison between a computationally guided pipeline for optimizing protein-based biotherapeutics and currently used strategies. The computational analysis of a candidate pool and/or the reduction of their aggregation by introducing solubilizing mutations offers a powerful alternative to expensive and blinded trial/error approaches, being cost-effective strategies to increase the success rate in the development of protein-based therapeutics.